Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 2001

View Archived Issues

Therapeutic efficacy of 6R-BH4 in autism

Shire highlights Q3 developments and updates product pipeline

Supratek initiates enrollment for SP-1049C phase II trial

Research collaboration targets proteins related to muscular dystrophy and neurodegenerative diseases

NicVAX nicotine vaccine completes preclinical safety testing

Investigational cancer drug GS-7836 moves to phase I testing

Development of SMART antibody for Crohn's disease continues based on preliminary findings

E.U. approval of Protopic recommended by CPMP

Launch of Xalcom/Xalacom begins in Europe

PhotoCure reports preliminary results from phase III trial of Metvix in basal cell carcinoma

AASLD news: Ceplene-containing combination therapies effective in hepatitis C

Adolor highlights Q3 clinical trial progress

Sustained antiviral effect, good safety of Coviracil in chronic HBV seen in 48-week phase I trial

Novuspharma updates R&D activities

Research and clinical programs continue to advance at Photogen

Clevudine exerts potent anti-HBV activity in early clinical trial

CTLA4Ig and LEA29Y demonstrate clinical and biological activity in RA

Major approval obtained by Pharmacia/Pfizer for new antiinflammatory/analgesic

Pexelizumab advances to pivotal trials in CABG/CPB patients; phase IIb data discussed at AHA

Antisense compounds designed at Isis targeting the ADAM10 gene

DNA encoding human acid-sensing ion channel cloned and characterized at Ortho-McNeil

Japan Tobacco claims new compounds potentiating neurite outgrowth

Novel series in development by Merck and Banyu has potential for diabetes, obesity, etc.

Inhibitors of P-450RAI as an approach to psoriasis and other retinoid-responsive disorders

P&G patents new MMP inhibitors useful for rheumatoid arthritis, osteoarthritis and cancer

Japanese lab presents new Rho kinase-inhibitory amides

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...